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Abstract
HIV-1 set-point viral load—the approximately stable value of viraemia in the first years of
chronic infection—is a strong predictor of clinical outcome and is highly variable across
infected individuals. To better understand HIV-1 pathogenesis and the evolution of the viral
population, we must quantify the heritability of set-point viral load, which is the fraction of
variation in this phenotype attributable to viral genetic variation. However, current estimates
of heritability vary widely, from 6% to 59%. Here we used a dataset of 2,028 seroconverters
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infected between 1985 and 2013 from 5 European countries (Belgium, Switzerland, France,
the Netherlands and the United Kingdom) and estimated the heritability of set-point viral
load at 31% (CI 15%–43%). Specifically, heritability was measured using models of charac-
ter evolution describing how viral load evolves on the phylogeny of whole-genome viral
sequences. In contrast to previous studies, (i) we measured viral loads using standardized
assays on a sample collected in a strict time window of 6 to 24 months after infection, from
which the viral genome was also sequenced; (ii) we compared 2 models of character evolu-
tion, the classical “Brownian motion” model and another model (“Ornstein–Uhlenbeck”) that
includes stabilising selection on viral load; (iii) we controlled for covariates, including age
and sex, which may inflate estimates of heritability; and (iv) we developed a goodness of fit
test based on the correlation of viral loads in cherries of the phylogenetic tree, showing that
both models of character evolution fit the data well. An overall heritability of 31% (CI 15%–
43%) is consistent with other studies based on regression of viral load in donor–recipient
pairs. Thus, about a third of variation in HIV-1 virulence is attributable to viral genetic
variation.
Author summary
The severity of the outcome of infection by a pathogen depends on many distinct factors.
These include the environment and the genetic sequences of both the host and the patho-
gen, among others. The fraction of variability in disease outcome explained by pathogen
genetic factors is termed “heritability”, because these factors are “inherited” by the new
host upon infection. Quantifying heritability is key to understanding the development of
the disease and the evolution of the virus. Here, we determined heritability of set-point
viral load (SPVL) in HIV-1. SPVL is the stable value of viraemia in asymptomatic infec-
tion and it is a strong predictor of disease severity. While heritability of SPVL has been
estimated using comparisons of viral genome sequences, this has resulted in widely vari-
able estimates of heritability. Using a large dataset of patients living in Europe, standard-
ised viral loads measures, and new methods, we obtain a more definitive estimate of HIV-
1 SPVL heritability in Europe at about 30%. Thus, a significant amount of the variation in
disease outcome is explained by the genetics of the virus.
Introduction
The outcome of infection by the human immunodeficiency virus-1 (HIV-1, henceforth “HIV”
for simplicity) is highly variable across individuals, with time to AIDS ranging from 2 years to
more than 20 years [1–4]. Quantifying the fraction of this variability explained by genetic vari-
ability in the virus is important to our understanding of the mechanisms of pathogenesis and
of the evolution of virulence [5].
Most studies have focused on set-point viral load (SPVL), which is a robust predictor of
time to AIDS [6]. Following HIV infection, viraemia rapidly increases and reaches a peak
before dropping precipitously once HIV-specific cytotoxic T-cells are produced by the
immune system [7,8]. After this transient peak has passed, about a month after infection, the
subsequent viraemia is much more stable [8] (although it slowly increases over the course of
untreated infection [9]). This relatively stable value defines the SPVL.
Viral genetic variation explains variability in HIV-1 pathogenesis
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The extent to which SPVL is determined by the viral genotype—the heritability of SPVL—
is defined as the fraction of phenotypic variance in SPVL attributable to variability in viral
genotypes [10–12]. The total variance in SPVL in the population may emerge from genetic var-
iation in the host, variation in the immune response, variation because of measurement error,
and variation in viral genotypes. Heritability estimates the contribution of the latter. Heritabil-
ity will determine the statistical power and necessary sample size to find viral molecular deter-
minants of virulence (for example, in genome-wide association studies [13]). Heritability also
determines the rate at which viral populations can evolve in response to selective pressures.
For example, it has been suggested that an intermediate value of SPVL maximizes viral fitness,
because higher SPVL translates into higher transmission rates but shorter disease duration
[14]. The rate at which HIV evolves to this optimal value depends on the heritability of SPVL
[15,16]. Alternatively, SPVL may change over time not because it is directly under selection
but because viral mutations that indirectly affect SPVL are under selection—for example, selec-
tion for immune escape or drug resistance. These ideas are not just theoretical possibilities:
recent meta-analyses have shown that the population mean SPVL varies over time in many
settings [17,18]. For example, in Europe, the mean SPVL of individuals who seroconverted at
the beginning of the 1980s was 10,000 copies/mL, whereas it is 30,000 copies/mL for those
who seroconverted at the beginning of the 2000s [18]. In contrast, in Botswana, it has been
hypothesised that a decline in set-point viral loads was caused by the evolution of costly cyto-
toxic T lymphocyte (CTL) escape mutations [19]; in Uganda, a decline in set-point viral loads
was explained by viral adaptation to a low optimal value under a transmission–virulence
trade-off [16]. As well as being a predictor of disease progression, viral load is also a strong pre-
dictor of transmission [20]: as a result, spatiotemporal variation in population SPVL will affect
epidemic trends. Thus, it is of both biological and public health interest to assess if trends in
SPVL can be explained by viral evolution.
Despite many studies into the determinants of virulence, estimates of the fraction of vari-
ability in SPVL attributable to genetic variability in HIV vary greatly. Heritability can be esti-
mated in 2 ways. Firstly, as the regression coefficient of recipient SPVL onto donor SPVL in a
set of transmission pairs. This is exactly analogous to the classical parent–offspring regression
used in quantitative genetics [10,11]. With this method, heritability of SPVL has been esti-
mated to be 33% (95% confidence interval 20% to 46%) in a meta-analysis of studies from sub-
Saharan Africa including 433 couples [21–23] (reviewed in [5]). Secondly, heritability can be
estimated from SPVL measurements and phylogenetic relationships between viruses (the
“phylogenetic mixed model” [24]). This comparative approach is based on the assumption that
the covariance between the SPVL of 2 individuals is proportional to their shared ancestry on
the viral phylogeny [24,25]. This assumption holds if SPVL evolution can be described by
Brownian motion (BM); the phylogenetic mixed model, and methods based on summary sta-
tistics such as Pagel’s lambda [26] or Blomberg’s K [27], were all developed under this assump-
tion. Estimation of heritability of SPVL using such comparative methods have yielded more
variable estimates of heritability: from 0% to around 60% in Switzerland depending on the
subset of the data [12,28]; no significant heritability in Uganda and the Netherlands [28]; and
6% (CI 3%–9%) in the United Kingdom [29]. Thus, no consistent picture has emerged from
these various reports.
Inconsistency between estimates may be caused by genuine differences in heritability across
populations, limited sample size, uncontrolled variability in SPVL, or limitations in the meth-
ods. Heritability may vary across populations and over time because it depends on the genetic
variability present in the viral population. For example, one may expect heritability of SPVL
to be larger in sub-Saharan Africa, where the viral population is very genetically diverse and
multiple subtypes are present [30,31], than in Europe or North America, where the viral
Viral genetic variation explains variability in HIV-1 pathogenesis
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population is dominated by subtype B [32]. Moreover, any uncontrolled source of environ-
mental variation—such as variability in the assays used to quantify viraemia, host variability,
or intermittent coinfections increasing HIV replication—decreases heritability. This may
explain why heritability was highest in the most homogeneous and strictly defined subset of
individuals in the Swiss HIV cohort study [12].
The methods used to measure heritability also have several limitations. Methods based on
donor–recipient regression do not rely on assuming a specific model of evolution of SPVL,
but they can only be applied to datasets that consist of transmission pairs and thus are not
suited to estimating heritability for large populations or in a wide range of settings. In addi-
tion, genetic confirmation of these transmission pairs is important to avoid downward-
biased estimates of heritability [21]. Phylogenetic methods typically include more data and
can be applied to more settings, because they use the SPVL measures of a whole cohort (not
only transmission pairs), together with the inferred phylogenetic relationships between viral
samples [24,25]. This comes at the cost of making specific assumptions on the model of
SPVL evolution (for example, the BM model is often assumed [12,29]). The BM model can
be interpreted as random unconstrained neutral evolution of virulence, defined as an intrin-
sic but unknown property of the virus that influences SPVL. In this model, when a patient is
infected, the patient’s SPVL is determined both by the virulence of the virus and by other
external factors, such as host genotype, dynamics of the host immune response, environmen-
tal factors, random effects, etc. The change in virulence over a time step Δt is drawn from a
normal distribution with mean 0 and stochastic variance proportional to Δt. Thus, changes
in virulence are random and independent from one time step to the next, resulting in no sus-
tained directional trend in virulence and a constant increase in the genetic variance of viru-
lence (and so SPVL) over time. These features may be considered unrealistic, as multiple
selective pressures may act upon HIV virulence [14,33], and directional trends in SPVL are
observed in some cohorts [17,18]. When virulence evolves under selection, inference of heri-
tability under BM is biased, usually downwards [34,35]. Similarly, phylogenetic methods
have little power to detect heritability when the evolution of virulence does not follow a BM
model [28].
We hypothesised that inconsistency between estimates in phylogenetic studies of SPVL her-
itability may have been caused by 5 factors: different viral genetic variance between settings,
limited sample size, heterogeneous SPVL measures and definitions, additional noise because
of imperfectly estimated phylogenies, and inappropriate use of the Brownian motion model
of character evolution. To overcome these limitations and understand what factors caused
inconsistencies, we measured heritability of SPVL in a large European cohort collaboration
(N = 2,028). We obtained blood samples of seroconverters from Belgium, France, the Nether-
lands, Switzerland, and the UK. Using a cohort of seroconverters allowed us to control for the
time since infection, which is associated with viral load because of time trends within patients.
We inferred heritability using a classical definition of SPVL, namely the mean (after a log10
transformation) of all viral loads measured between 6 and 24 months after infection. Averag-
ing multiple viral load measurements from different time points reduces error variance but
may also average out biologically important fluctuations in viral genotype or phenotype within
the patient. We also remeasured viraemia using a standardized choice of assay on a single sam-
ple taken between 6 and 24 months after infection and before antiretroviral therapy was started
(“gold standard viral load”, GSVL), and we reconstructed the viral genome from the same sam-
ple. The controlled time window of 6 to 24 months limits variability because of the stage of the
infection for both the SPVL and GSVL measures. Additionally, the GSVL measure was defined
to limit spurious variation because of variability in assays, to more closely link the viral geno-
type and phenotype by measuring them from the same sample and to expose variation because
Viral genetic variation explains variability in HIV-1 pathogenesis
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of within-host fluctuations in genotype and phenotype that is averaged out in SPVL measures.
Henceforth, we use the term ‘viral load’ to mean either SPVL (as classically defined) or GSVL.
To improve the resolution of our inferred phylogenies, we generated whole viral genomes
rather than genotypes based on the polymerase (pol) gene as in previous studies. To avoid the
limitations associated with an inappropriate model of character evolution, we compared the
classical phylogenetic mixed model based on BM to the Ornstein–Uhlenbeck (OU) model,
which includes stabilising selection on viral load. The OU model has been widely used in com-
parative biology since its introduction in the 1990s [36]. Recently, the OU model was argued
to be more appropriate than the BM model to quantify heritability of viral traits [34] and was
applied to several datasets ([35] and the present study).
Using a large dataset, carefully measured viral load, whole-genome HIV sequences, and
new methods, we showed that the heritability of GSVL is 31% (CI 15%–43%), and the herita-
bility of SPVL is 21% (CI 10%–36%).
Results
Viral load is significantly determined by viral genetic factors
We fitted the following 3 stochastic models, presented in order of increasing complexity. (i) A
null model with only a random component uncorrelated across the tips of the phylogeny,
implying zero heritability. (ii) The BM model in which viral load evolves randomly along the
branches of the tree, leading to unconstrained increases in genetic variance over time—the
model most commonly used in comparative studies [24,25]. (iii) The OU model, which
includes a random component similar to BM as well as stabilising selection that brings viral
load towards an optimal value and maintains variance at a stochastic equilibrium level [36]
(Fig 1A, Materials and methods). Both BM and OU, like all common models of character evo-
lution on phylogenies, assume that evolution occurs continuously on the branches of the phy-
logenetic tree and make no distinction between within-host and between-host evolution.
The consequences of these models of character evolution on viral load can be described as a
linear model with a fixed effect representing the expectation of viral load at the tips and a ran-
dom effect with a covariance structure depending on the phylogenetic tree and the model of
character evolution (Materials and methods). We also adjusted for the confounding covariates
sex, transmission mode, age, ethnicity, and viral load assay by including them as additional
fixed effects in the linear model. If these factors affected the viral load, they would have con-
tributed to the environmental variance in viral load. Failing to adjust for these covariates
would have then inflated estimates of heritability if these factors were clustered in the phylog-
eny. We did not adjust for the covariates “country” and “viral subtype” in the main analysis as
they are correlated with viral genotype.
Viral load was either GSVL, a measure of viraemia remeasured on the same sample as used
for viral genetics using a standardized choice of assay (Materials and methods), or the tradi-
tional SPVL measure, which is classically defined as the mean of log10 viral load for samples
from multiple longitudinal samples during a defined period after the first HIV-positive test.
The phylogenetic tree was computed from whole-genome sequences reconstructed from
short-read next-generation sequence data [37] and stripped of positions associated with previ-
ously identified drug-resistant mutations [38,39] and CTL escape mutations [40] (Materials
and methods) (S1 Fig). Mutations at these positions are under strong selection and may inde-
pendently evolve in different branches of the tree, thus leading to incorrect phylogenetic infer-
ence. Results were similar when including these mutations (S3 Table).
Models in which viral load is partly determined by viral genetic factors evolving along the
phylogenetic tree had a significantly better fit than the null model, but there was no strong
Viral genetic variation explains variability in HIV-1 pathogenesis
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support for the OU over the BM model (Table 1, model comparison based on Akaike Infor-
mation Criterion (AIC), ΔAIC = –19.6 for BM, ΔAIC = –21.4 for OU compared to the null
model). The OU model with stabilising selection was more strongly supported in the set of
all subtypes.
Fig 1. Predictions from the Brownian motion (BM) and Ornstein-Uhlenbeck (OU) models of evolution. (A) Illustration of the models of character
evolution on a phylogeny (top panel), showing unconstrained neutral evolution leading to increasing genetic variance under the BM model (middle
panel) versus stabilizing selection around an optimum θ under the OU model, which results in stable variance over time (bottom panel). Edges of the
phylogeny were arbitrarily colored for illustrative purposes. (B) The distribution of gold standard viral load (GSVL) over evolutionary time (as quantified
by root-to-tip distance [i.e., distance from the common ancestor as assessed by the phylogeny]). Points are the data; boxplots show the median, lower,
and upper quartiles, and the whiskers are the lower and upper quartile minus or plus 1.5 times the interquartile range for 8 bins of equal size. (C) The
correlation coefficient of GSVL across 511 phylogenetic cherries in the subtype B phylogeny as a function of the patristic distance between cherries.
Phylogenetic cherries were grouped by patristic distance in 10 bins of equal size. Points are the data, the dashed line is a decreasing exponential fit on
the data, and thick lines show predictions from the maximum likelihood (ML) BM and OU models. The large points at patristic distance 0 show the
population-level heritability estimated under the BM (blue) and OU (red) model. The data used in the figure are provided as S1 Data.
https://doi.org/10.1371/journal.pbio.2001855.g001
Viral genetic variation explains variability in HIV-1 pathogenesis
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Heritability of GSVL among subtype B samples is 31%
The maximum likelihood (ML) models of character evolution implied heritability for GSVL of
17% [8%–26%] under the BM model and 31% [15%–43%] under the OU model (Table 1, Fig
2). Heritability is defined as the fraction of phenotypic variance explained by genetic variance
in a given population. More precisely, we estimated broad-sense heritability: the contribution
to phenotypic variance of all genetic variation (including variation generated by epistatic
effects between loci). This contrasts with narrow-sense heritability, which quantifies only the
Table 1. Summary of model fit for the subset of subtype B viruses and for all subtypes.
Subtype Model Measure N AIC AIC
weight
VE σ2 α Optimum θ h2
B NULL GSVL 1,581 3,461.7 0 0.52 (0.47–0.55) - - - 0 (0–0)
BM GSVL 1,581 3,442.1 0.29 0.43 (0.39–0.47) 0.5 (0.22–0.76) - - 0.17 (0.08–
0.26)
OU GSVL 1,581 3,440.3 0.71 0.35 (0.29–0.43) 3 (0.96–4.8) 8.5 (2.4–10) 4.4 (3.7–5.1) 0.31 (0.15–
0.43)
NULL SPVL 1,581 3,355.6 0 0.48 (0.44–0.51) - - - 0 (0–0)
BM SPVL 1,581 3,343.2 0.66 0.42 (0.37–0.46) 0.35 (0.14–0.54) - - 0.13 (0.05–
0.2)
OU SPVL 1,581 3,344.5 0.34 0.37 (0.29–0.42) 1.7 (0.44–3.5) 7.6 (1.2–10) 4.1 (3.5–4.9) 0.21 (0.1–
0.36)
NULL CD4
slope
1,170 377 0.02 0.08 (0.067–
0.096)
- - - 0 (0–0)
BM CD4
slope
1,170 370.8 0.55 0.07 (0.063–
0.08)
0.048 (1e-06–
0.088)
- - 0.11 (0–0.19)
OU CD4
slope
1,170 371.3 0.43 0.071 (0.056–
0.079)
0.043 (1e-06–
0.37)
0.095 (1.1e-
06–10)
–4.9 (–520000 to
0.041)
0.1 (0.01–
0.27)
All NULL GSVL 2,028 4,474.8 0 0.53 (0.49–0.55) - - - 0 (0–0)
BM GSVL 2,028 4,463.3 0 0.45 (0.41–0.49) 0.38 (0.19–0.62) - - 0.17 (0.09–
0.29)
OU GSVL 2,028 4,451.6 1 0.35 (0.29–0.43) 3.6 (1.6–5.1) 10 (6.9–10) 4.2 (3.9–4.6) 0.32 (0.18–
0.44)
NULL SPVL 2,028 4,395.4 0 0.51 (0.47–0.53) - - - 0 (0–0)
BM SPVL 2,028 4,388.4 0.08 0.45 (0.42–0.48) 0.3 (0.11–0.44) - - 0.14 (0.05–
0.22)
OU SPVL 2,028 4,383.5 0.92 0.38 (0.32–0.47) 2.6 (0.32–3.6) 10 (3.5–10) 4.2 (3.5–4.7) 0.24 (0.06–
0.34)
NULL CD4
slope
1,476 471.7 0.01 0.08 (0.069–
0.091)
- - - 0 (0–0)
BM CD4
slope
1,476 464.3 0.45 0.072 (0.065–
0.08)
0.033 (0.0016–
0.058)
- - 0.1 (0.01–
0.18)
OU CD4
slope
1,476 463.9 0.54 0.069 (0.058–
0.077)
0.081 (1e-06–
0.38)
2.9 (1.6e-06–
10)
–0.3 (–170000 to
0.051)
0.13 (0.01–
0.25)
Maximum likelihood estimates are given with 95% parametric bootstrap confidence intervals, accounting for uncertainty because of finite sample size and
uncertainty in phylogenetic reconstruction (N = 100 bootstraps, see text for details). Three phylogenetic models (NULL, BM, and OU) are presented for 3
viral phenotypes: GSVL and SPVL are in units of log10 viral copies/mL of blood and CD4 slope is in units of cells/mm3/day. N is the sample size. AIC is the
Akaike Information Criterion; AIC weight for model i (NULL, BM, or OU) is defined as wi ¼ exp½ðaici   minðaicÞÞ=2P3
i¼1
exp½ðaici   minðaicÞÞ=2
. VE is the environmental variance, including
host factors and error variance (but not variability in assay, as the linear regression adjusts for assay). σ2 is the stochastic variance governing evolution of
the viral genetic factors along the phylogeny. α is the strength of stabilising selection in the OU model. The optimum θ is the optimal trait in the OU model. h2
is the heritability. BM, Brownian motion; GSVL, gold standard viral load; OU, Ornstein–Uhlenbeck; SPVL, set-point viral load.
https://doi.org/10.1371/journal.pbio.2001855.t001
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contribution of additive effects of individual genetic variants [35]. We estimated heritability by
resimulating the ML model of viral load evolution on the tree. A simulation attributed a value
of viral load to each tip of the tree as the sum of a viral genetic component and an environmen-
tal component (the latter including epidemiological covariates). Heritability was the variance
of the genetic component (across tips) divided by the total variance in the simulations. Because
the models of evolution are stochastic, each run gave a different value of heritability; therefore,
we reported the mean heritability across 1,000 stochastic simulations. We also developed an
analytical expression for the expectation of heritability as a function of model parameters that
allows faster calculations and proved very accurate (Materials and methods). In accordance
with theoretical expectations [35], assuming a BM model of character evolution led to lower
heritability than assuming an OU model. The BM model theoretically results in steady expan-
sion of the genetic variance over phylogenetic time. A SPVL variance similar at tips closer to
Fig 2. Maximum likelihood estimates of heritability (points) and bootstrap confidence intervals (segments) for
subtype B sequence. This is shown for the BM and OU model and the GSVL and SPVL measures of viral load for the
whole-genome phylogeny; for the OU model and GSVL on the phylogeny inferred only from gag, pol, and env genes
(light grey box); and for several stratifications of the data, only when the size of the subset was greater than 400 (dark
grey box). CH: Switzerland, NL: the Netherlands; male sex; MSM. The data used in the figure are provided as S1 Data.
https://doi.org/10.1371/journal.pbio.2001855.g002
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the root and at tips further away from the root goes against this prediction and leads to a
downward bias in the estimated genetic variance and heritability. In contrast, the OU model
allows high heritability even with a stable variance (Fig 1A). In our data, epidemiological
covariates (sex, transmission mode, age, ethnicity, assay) would have inflated heritability by
4% were they not accounted for (heritability of GSVL without adjustment for these covariates
was at 21% and 35% under BM and OU), with an effect of sex in particular. This means some
of these covariates affected viral load and were clustered in the phylogenetic tree. Specifically,
in the subset of subtype B, for GSVL, under the null model, males had +0.3 log10 copies/mL
higher GSVL than females (CI 0.15–0.45) (type II analysis of variance, p = 0.0002). Mode of
transmission, age, and ethnicity did not have a significant effect in the subset of subtype B (S4
Table), although mode of transmission had a significant effect when considering all partici-
pants (S5 Table), with men having sex with men (MSM) transmission associated with +0.14
[CI 0.046–0.24] log10 copies/mL higher GSVL compared to heterosexual transmission. The
type of assay had an effect on SPVL (type II analysis of variance, p = 0.0019) but no effect on
GSVL (p = 0.24). This confirms the better standardisation of the GSVL measure. Effects were
similar under the BM and OU model. Lastly, including “country” as a covariate in the phyloge-
netic regression lowered heritability by 5% to 6% (S3 Table). This difference partly represents
genuine heritability because the viral genotype is expected to differ by country.
We quantified uncertainty on the parameters and on heritability using parametric boot-
strapping on the bootstrapped trees. This method combines uncertainty because of finite sam-
ple size and uncertainty in the phylogenetic tree inference. For each of the 100 bootstrap trees,
we simulated a stochastic outcome of the ML model, reinferred ML parameters from these
simulations, and calculated the confidence intervals on these reinferred parameters. Uncer-
tainty on heritability was large for the OU model, ranging from 15% to 43%, in spite of the
large dataset (N = 1,581).
Heritability of GSVL was higher than heritability of SPVL. This difference, however, was
not due to higher environmental variance for SPVL but rather was due to higher genetic vari-
ance for GSVL (environmental variance VE was similar for the 2 measures, but the stochastic
variance σ2 describing evolution of the genetic component is higher for GSVL, Table 1).
The structuring of the viral population into several subtypes did not contribute much to
heritability, as heritability was only slightly higher across all subtypes (Table 1), and we did not
detect any effect of subtype on viral load (type II analysis of variance, p = 0.65, S5 Table). The
interpretation of heritability across all subtypes is difficult, as many of the nonsubtype B
sequences were recombinants. This means that in the phylogenetic tree of all subtypes, the
topology, and branch lengths between subtypes cannot be interpreted in terms of the amount
of evolution on a line of vertical transmission, hindering phylogenetic interpretation. Because
of the diversity of non-B viruses in our sample, we did not have sufficient data to individually
estimate heritability for specific non-B subtypes.
We next stratified the analysis by country, sex, and mode of transmission. To first estimate
the power to detect heritability in smaller subsets of data, we systematically subsampled the
main dataset at random and measured maximum likelihood heritability and confidence inter-
vals as a function of sample size (S2 Fig). We found that accurate and precise estimation of her-
itability required samples of at least 500 individuals, especially when using the OU model of
character evolution. Accordingly, we found no significant heritability in most stratifications of
the data. Heritability measured separately within each country was significant only in the
Netherlands, at 26% (12%–60%) (S2 Table, N = 434, ΔAIC = –12.2 for OU compared to the
null model). In Switzerland, the largest cohort in this study, GSVL was not significantly herita-
ble (S2 Table, N = 742, ΔAIC = +2.1 for OU compared to the null model). This could reflect
the limited genetic diversity of our Swiss samples; in other countries, the lack of detected
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heritability is most likely due to limited power to detect a phylogenetic signal. In males infected
by subtype B viruses (N = 1,446), GSVL heritability was 16% under BM and 32% under OU,
but heritability was not significant in females (N = 135). In MSM infected by subtype B viruses
(N = 1,196), GSVL heritability was 17% under BM and 30% under OU, but heritability was not
significant in injecting drug users (IDUs) (N = 110) and heterosexuals (N = 211).
Goodness of fit tests
Both BM and OU models fitted the data well. One major difference in the prediction of the 2
models is that in BM, the genetic variance keeps increasing with genetic distance as neutral
genetic variation accumulates, whereas in OU genetic variance initially increases and then
eventually reaches equilibrium between generation of variation and stabilising selection (Fig
1A). The maximum likelihood BM and OU models both predicted an increasing genetic vari-
ance at a rate of +0.0024 log10 copies
2/mL2/year for BM and +0.0011 log10 copies
2/mL2/year
for OU (S3 Fig). The intermediate increase in variance predicted by the OU model means that
the distribution of viral loads has not yet converged to its steady state. In our dataset, the aver-
age viral load was constant over time, and phenotypic variance increased over time in GSVL at
+0.01 log10 copies
2/mL2/year but did not significantly increase in SPVL (S1 Table).
As well as predicting the variance, the models predict the covariance structure of the viral
loads at the tips of the phylogeny. We assessed goodness of fit on the subset of 511 phylogenetic
cherries (pairs of adjacent tips that are each mutually closest to each other) on the tree of sub-
type B viruses. In addition to testing goodness of fit, focusing on cherries allows phylogenetic
approaches to be compared to the donor–recipient regression that are based on classical quan-
titative genetics [28,35]. Indeed, phylogenetic cherries that are genetically very similar (sepa-
rated by a small patristic distance) on a phylogenetic tree are more likely to be donor–recipient
pairs than genetically distant pairs [41]. We computed the Pearson correlation coefficient
between viral load values across cherries, stratified by the patristic distance (the distance
between the 2 tips) (Fig 1C). In the limit in which patristic distance is 0, the expected value of
both correlation coefficients is equal to heritability (S2 Text, see also [35]). For OU, the correla-
tion decreases with patristic distance. For BM, all else being equal, the correlation should in
theory be independent of patristic distance (Materials and methods). However, here we see
that for the BM model the correlation decreased with patristic distance, because those pairs of
tips separated by a large patristic distance tend to also have less shared ancestry. In accordance
with the predictions of both models, the correlation coefficient for GSVL of cherries separated
by a small patristic distance was around 30%, not far from the predicted heritability of 17%
(under BM) and 31% (under OU) (Fig 1C). The observed negative relationship between the
correlation coefficient and the patristic distance resembled closely the prediction from both
models (Fig 1C).
Variation in heritability across the genome
When using only the phylogenetic information contained in a single gene instead of the whole
genome, we found heritability for the OU model was 27% (14%–36%) in the gag gene, 28%
(16%–39%) in pol, and 21% (11%–39%) in env (Table 2, Fig 3). The lower heritability for each
gene independently compared with the whole genome (h2 = 31%) was expected. In the limit of
no recombination, the phylogenetic history of all genes is the same: thus, with perfect phyloge-
netic resolution, heritability is the same across genes and equal to total heritability for the whole
genome. At the other limit where the 3 genes evolve independently (linkage disequilibrium
between them is 0), the heritability for each gene reflects the contribution of molecular variation
at that gene on total variation, and whole-genome heritability is the sum of heritability across
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genes. Indeed, if the viral load can be written v = ggag + gpol + genv + e where the terms in g
denotes the additive genetic contributions of each gene and e denotes the effect of the environ-
ment, then fitting a model of character evolution on the gag tree estimates ggag, while gpol + genv
is subsumed in e because this quantity is randomly distributed on the gag tree by the assump-
tion of linkage equilibrium.
At a finer scale, when inferring the heritability across the genome in 17 overlapping win-
dows that are 1,000 base pairs in length separated by 500 base pairs, we found accordingly
that heritability was almost always lower than for the whole-genome inference. Heritability
was highest around the region where the gag and pol genes overlap and lowest in the region
between the pol and env genes, including the vif, vpr, and vpu genes (Fig 3). Linkage disequilib-
rium dropped rapidly with genetic distance and was small when the distance was greater
than 100 bp (S4 Fig). Confidence intervals reflecting phylogenetic uncertainty (Materials and
methods) do not overlap between the low- and high-heritability regions. These observations
suggest 2 distinct island contributions to heritability, 1 from the low-diversity region coding
for the replication machinery (gag–pol) and the second from the high-diversity region coding
for the envelope gene.
Heritability of the CD4 cell count slope is 11%
Lastly, we investigated the heritability of another viral phenotype, the CD4 cell count slope (the
rate at which the patient’s CD4 cell count declines). CD4 slope was not found to be heritable in
a previous analysis [12]. We computed the CD4 slope for N = 1,476 patients with at least 5 CD4
measures after the date of the first positive HIV test and before antiretroviral therapy. Models
in which CD4 slope was partly determined by viral genotype evolving along the phylogeny were
favoured over the null model (Table 1, ΔAIC = –6.2 for BM, ΔAIC = –5.7 for OU compared to
the null model). Heritability was weak, at 11% [0%–19%] in the favoured BM model (the ML
OU model has weak stabilising force, and the inferred heritability was similar to that of the BM
model). The coefficient of determination of the relationship between CD4 slope and viral load
was R2 = 5.2% for GSVL, R2 = 7.4% for SPVL. This weak relationship is similar to that found
previously [42,43] and may partly be explained by the noisiness of the CD4 slope measure and
the difference between viral load and CD4 count in the blood versus in the whole body.
Discussion
Using a large dataset of whole-genome HIV sequences (N = 2,028) from patients with a known
seroconversion date with carefully measured viral load, we established that viral genetic factors
Table 2. Summary of model fit for GSVL, for subtype B, for each gene. Parameters as in Table 1.
Model Gene N AIC AIC weight VE σ2 α Optimum θ h2
NULL gag 1,569 3,378.7 0 0.5 (0.46–0.53) - - - 0 (0–0)
BM 1,569 3,351.5 0.14 0.41 (0.37–0.44) 0.9 (0.48–1.3) - - 0.17 (0.09–0.26)
OU 1,569 3,347.8 0.86 0.36 (0.31–0.42) 3.2 (1.4–4.5) 10 (3.9–10) 4.3 (3.7–5) 0.27 (0.14–0.36)
NULL pol 1,377 2,814.2 0 0.45 (0.41–0.48) - - - 0 (0–0)
BM 1,377 2,790.5 0.34 0.36 (0.32–0.42) 0.72 (0.29–1.1) - - 0.19 (0.08–0.28)
OU 1,377 2,789.2 0.66 0.32 (0.26–0.36) 2.2 (0.83–3.8) 7.2 (1.4–10) 4.3 (3.6–5.1) 0.28 (0.16–0.39)
NULL env 1,487 3,016.3 0 0.44 (0.39–0.47) - - - 0 (0–0)
BM 1,487 2,996 0.56 0.38 (0.32–0.42) 0.24 (0.085–0.42) - - 0.13 (0.04–0.23)
OU 1,487 2,996.5 0.44 0.34 (0.25–0.39) 0.87 (0.3–3.4) 3.8 (0.87–10) 4.3 (3.5–5) 0.21 (0.11–0.39)
AIC, Akaike Information Criterion; BM, Brownian motion; OU, Ornstein–Uhlenbeck.
https://doi.org/10.1371/journal.pbio.2001855.t002
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account for 20% to 30% of variation in viral load in Europe. This estimate of heritability is con-
sistent with those obtained with donor–recipient regression (around 30% [5]), unlike results of
previous phylogenetic studies [12,29]. It agrees with a recent analysis performed on 8,483
patients with pol sequences from the UK, reporting a lower bound for heritability of SPVL at
25% [35]. We hypothesized that the large variation across previously published phylogenetic
estimates could be due to genuine biological differences across cohorts, limited sample sizes,
less rigorous selection criteria for patient inclusion leading to heterogeneous viral load mea-
sures, less well resolved phylogenies, and/or use of methods based on inappropriate models of
character evolution. We found an effect of limited sample sizes and the model of character evo-
lution. However, there was little evidence for genuine biological differences across cohorts
included in this data.
Fig 3. Maximum likelihood estimates of heritability across the genome. Heritability was inferred for overlapping windows of 1,000 bp
separated by 500 bp for the Ornstein–Uhlenbeck (OU) model (black bullets) and the Brownian motion (BM) model (grey bullets). The horizontal
dashed lines are the whole-genome heritability estimates. The 3 colored segments show heritability for gag, pol, and env genes in blue, green, red
(for OU only). Confidence intervals (grey and colored regions) reflect phylogenetic uncertainty. The largest heritability is in the region where gag
and pol overlap. We also show entropy—a measure of genetic diversity—along the genome (dashed curve and right axis). Entropy at a position
was calculated as −Σi 2 {A,C,G,T}pi log(pi), and we show the average entropy over 200-bp windows. The data used in the figure are provided as S1
Data.
https://doi.org/10.1371/journal.pbio.2001855.g003
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This study provides several methodological recommendations for the estimation of herita-
bility. Firstly, precise and accurate estimation of heritability required a sample of at least 500
individuals in our cohort (S2 Fig). Limited sample sizes can generate substantial heterogene-
ities across estimates, in accordance with previous results showing limited power to detect her-
itability in existing datasets, and large confidence intervals [28]. Secondly, we compared 2
models of character evolution: BM and OU (the latter including stabilising selection). The BM
model of evolution was used in most previous studies of HIV viral load heritability, while the
OU model was only recently applied to HIV data ([35] and the present study). In this dataset,
we found the 2 models were almost equally supported for subtype B, and the OU model was
more supported for all subtypes combined. OU implied higher heritability than BM. Support
for the OU model was stronger in the set of all subtypes (Table 1). Because the tree of all sub-
types spans a larger phylogenetic distance than the tree of subtype B (the root-to-tip distance is
almost twice as large), the BM model fits less well the covariation of viral load between tips and
the observed phenotypic variance. In general, we suggest the OU model may better describe
viral load evolution for 3 reasons. (i) The OU model, with stabilising selection, is a better fit on
previously analysed data from the UK [29] and Switzerland [12], leading to consistent esti-
mates of heritability at about 30% in both cohorts [35]. (ii) Data on 56 donor–recipient pairs
show that the correlation coefficient between viral loads of the donor and that of the recipient
decreases as the recipient viral load is measured later in infection [44]. This is in accordance
with the OU model, in which stabilising selection progressively erases the correlation between
donor and recipient viral loads. But it is not in accordance with the BM model, in which the
correlation coefficient does not depend on the time elapsed between donor and recipient but
only on the amount of evolutionary ancestry that they share. (iii) The OU model, unlike the
BM model, is compatible with the hypothesis that viral load is under a transmission–virulence
trade-off favouring those viruses giving intermediate viral loads [14]. Under this trade-off,
viral load is under stabilising selection as in the OU model, because very low viral loads (result-
ing in very low transmission rates) and very high viral loads (resulting in very short duration
of infection) do not allow much onward transmission of the virus, such that viral load cannot
drift unconstrained to very low or very high values. Consistent with this hypothesis, we found
that the optimal GSVL was 4.4 log10 copies/mL in subtype B viruses (CI [3.5–5.2]), an estimate
close to the optimum inferred using epidemiological data [14,16]. Unfortunately, although the
OU model is probably more biologically realistic, one must keep in mind that with this model,
any temporal trend in viral load will be interpreted as caused by evolution of viral genetic fac-
tors. For example, in our dataset (in which SPVL did not significantly change over time), add-
ing a temporal trend of +0.02 log10 copies/mL/year (comparable to what has been observed in
various European and North American cohorts [17,18]) resulted in the OU model being much
more favoured (ΔAIC = 12 compared to the BM model). The BM model is unlikely to result in
a sustained temporal trend, especially when the sample size is large. Yet, a temporal trend in
viral load may be due to uncontrolled environmental factors—for example, a changing preva-
lence of coinfections [45] or variability in the viraemia assays—and not necessarily to viral evo-
lution. In a dataset presenting a significant temporal trend in which OU is the best model, the
dataset may be analysed with the temporal trend removed to check that the correlation struc-
ture of viral load also corresponds best to the OU model. Thirdly, our results reconcile estima-
tion of heritability based on donor–recipient pairs (which consistently estimate heritability at
around 30%) and those based on phylogenetic analysis. If we assume the phylogenetic cherries
separated by a small patristic distance are indeed sampled from donor–recipient pairs, the her-
itability estimated here by donor–recipient regression was similar to the prediction based on
the phylogenetic analysis (Fig 1C). We also derive formal links between donor–recipient
regressions and phylogenetic models (S2 Text).
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In this large European cohort, there was no evidence that heritability differed between
countries. Given the small sample sizes for each country, we had limited power to detect such
differences. However, the similar phenotypic variance across countries and the fact that
sequences from different countries are interspersed in the tree also suggested genetic variance
in viral load was similar across countries. We found significant heritability only in the Nether-
lands—26% (N = 434, S2 Table). We found no significant heritability in the 742 subtype B
sequences from Switzerland (S2 Table). Previous studies have estimated heritability of SPVL in
Switzerland at around 60% but only when focusing on the subset of MSM patients with at least
3 viral load measures with little fluctuations across measures [12,28], a subset accounting for
20% of all the data; no significant heritability was found when using all of the data. The limited
number of samples from the UK (N = 87, S2 Table) made it difficult to compare our results
with a previous study finding a heritability of 6% in the UK [29].
We estimated the heritability of 3 viral phenotypes: the single viral load GSVL measured in
a standardised way, SPVL, and the rate of CD4 decline. GSVL had higher genetic variance
than SPVL, resulting in heritability of 31% for GSVL compared to 21% for SPVL, and we sug-
gest this is due to the closer link between the viral sequence and the phenotype, both obtained
from the same sample (S1 Text). However, SPVL was a better predictor of CD4 decline, as it
explained R2 = 7.4% of the variance in CD4 decline, while GSVL explained R2 = 5.2%. This is
perhaps not surprising: CD4 decline and SPVL are both temporal averages summarising viru-
lence over a period of time, whereas GSVL is a single measurement typically taken at the
beginning of infection (median time between date first positive and sample = 266 days). Note
though that assay variability significantly contributed to variation in SPVL (S4 Table), showing
the importance of adjusting for assay type when estimating heritability of SPVL. In our defini-
tion of heritability, assay error and variability in assays contributed to the denominator (total
phenotypic variance). Yet, this variation does not correspond to biological variation in the true
trait but to variation caused by imperfect measurement. In principle, we should remove this
source of variance from the denominator to obtain the phenotypic variance in the true trait,
and this will result in higher heritability. This effect would be negligible for assay variability,
which represents only a small fraction of the total variance (S4 Table). Similarly, a plausible
value for assay error at 0.04 log10 copies
2/mL2 (Materials and methods) would result (with a
phenotypic variance of 0.54 log10 copies
2/mL2 and heritability at 31%) in a slightly higher heri-
tability of 0.31 x 0.54 / (0.54–0.04) = 33%. Lastly, 11% of variation in the rate of CD4 cell count
decline was explained by viral genetic variation. The small correlation between CD4 decline
and viral load (around 5%), the CD4 decline heritability of 11%, and the viral load heritability
of 31% can be explained by the existence of several classes of viral variants: (i) variants causing
more intense exploitation of CD4 cells resulting in faster CD4 depletion and greater viral load,
contributing to the heritability of CD4 decline and of viral load; (ii) variants increasing viral
load without intensifying the exploitation of CD4 cells, contributing to the heritability of viral
load only; and (iii) variants intensifying the exploitation of CD4 cells without increasing viral
load, contributing to the heritability of CD4 decline only.
Both models of character evolution assume an additive effect of the viral genotype and an
“environment” effect (including host factors). A limitation of this study is that host genotype
data was not available, in particular for the host class I HLA alleles, and therefore we could not
control for this important factor [46] in the regression. Moreover, variability in viral load may
depend on interactions between viral and host genetic factors [13,47], in particular between
host class I HLA alleles and viral CTL epitopes. Our model assumes additive contributions of
the host and the virus and would force the (host genotype) x (viral genotype) interaction vari-
ance into the 2 additive components. This calls for the development of new methods to mea-
sure the fraction of variance determined by virus–host interactions [47].
Viral genetic variation explains variability in HIV-1 pathogenesis
PLOS Biology | https://doi.org/10.1371/journal.pbio.2001855 June 12, 2017 14 / 26
The confirmation that a significant fraction of variability in viral load is determined by viral
genetic factors motivates searching for individual viral genetic variants responsible for varia-
tion in viral load. The finding of 2 distinct islands’ contributions to heritability, 1 from the
replication machinery (gag and pol genes) and the second from the envelope gene, will guide
this search. A previous viral genome-wide association study did not find any significant viral
genetic variation associated with viral load [13] but was only powered to detect individual
effects accounting for 4% or more heritability. This suggests that the effects of individual vari-
ants are small, requiring large sample sizes for their discovery. Viral load may also be deter-
mined by epistatic effects between mutations, the detection of which would require even larger
sample sizes. Knowledge of these molecular variants would allow us to relate changes in fre-
quency of these variants to the observed temporal trends in viral load [17–19], and most
importantly, would provide new insights into HIV pathogenesis, a fascinating but challenging
task [5].
In conclusion, around 30% of variation in viral load was explained by viral genetic variation
in these European cohorts. This study highlights the need for large datasets, comparison
between different models of character evolution, and goodness of fit tests to consistently esti-
mate heritability of viral load in HIV-1 infection and so explains and resolves the inconsistency
in previously published estimates.
Materials and methods
Patient population
We selected HIV-positive seroconverters from the Antwerp cohort in Belgium (BE), the
Swiss HIV Cohort Study in Switzerland (CH), the ANRS PRIMO Cohort in France (FR), the
ATHENA cohort in the Netherlands (NL), and the UK register of seroconverters in the UK—
all part of the BEEHIVE (“Bridging the Evolution and Epidemiology of HIV in Europe”) col-
laboration. These were selected as the set of all patients meeting the study’s inclusion criteria,
for which we had complete clinical and virus genetic data at the time of analysis. The inclusion
criteria were the following. (i) Participants were seroconverters (i.e., the first positive test was
less than 1 year after the last negative test), or the participant presented with evidence of recent
infection (laboratory evidence or seroconversion illness), ensuring the date of infection was
known precisely. (ii) No antiretroviral therapy was taken in the first 6 months following the
first positive test. (iii) At least 1 viral load or 1 sample from which viral load can be determined
was taken between 6 and 24 months following the first positive test. (iv) At least 1 sample of at
least 500 μL of frozen EDTA plasma or serum was taken between 0 and 24 months following
the first positive test while antiretroviral therapy (ART)-naive. We also collected information
on age, sex, and mode of transmission. All patients consented to this study. All studies within
the cohorts were approved by in-country institutional review boards, and the overall BEE-
HIVE study, which only accessed anonymised data, was approved by the ethics panel of the
European Research Council.
Viral load measures
The stable value of viraemia after acute infection and before the onset of AIDS (our pheno-
type of interest) was calculated in 2 ways. First, the viral load was remeasured in a standard-
ized way, on a single blood sample taken more than 6 months and less than 24 months after
the first positive HIV test and before the start of ART. If viral load had been previously mea-
sured with 1 of 3 assays (COBAS AmpliPrep/COBAS TaqMan HIV-1 Test, v2.0 from Roche;
Abbott RealTiMe HIV-1 Assay from Abbott; Quantiplex HIV-1 RNA Assay, version 3.0
from Chiron Diagnostics, Emeryville, CA), on the same visit when the sample used to
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determine the viral sequence was taken, we did not repeat the assay. Otherwise, viral loads
were repeated with COBAS AmpliPrep/COBAS TaqMan HIV-1 Test, v2.0 on the same sam-
ple used to determine the viral sequence. We defined the GSVL as log10 of the single viral
load (in copies per mL) measured in this way. In several cases, the GSVL was below detection
limit, which may be due to genuinely low viraemia or assay failure, but the assay could not
be repeated because of material shortage. We eliminated from the analysis the undetectable
GSVL values with SPVL greater than 3 log10 copies/mL (N = 1 value eliminated). The error
variance of the assay used for GSVL is between 0.01 log10 copies
2/mL2 (standard deviation of
0.1 copies/mL estimated in a standardised way using aliquots of the same sample [48]) and
0.25 log10 copies
2/mL2 (standard deviation of <0.5 log10 copies/mL estimated from the repli-
cated viral load measures for problematic samples in this study). An intermediate value of
0.04 log10 copies
2/mL2 is plausible.
Second, we used the series of viral loads previously measured on the same patients to define
the set-point viral load (SPVL), calculated as the average log10 (viral load, in copies per mL) for
all viral load measurements available between 6 and 24 months after the first positive HIV test
(using different assays).
For both the GSVL and the SPVL measures, we adjusted for the potential impact of assay
type on viral load within the phylogenetic regression.
CD4 count measures
Additionally, we quantified virulence of the virus using the rate of CD4 decline in patients. We
selected patients who had at least 5 CD4 count measures between the date of the first positive
HIV test and the date that ART was first prescribed. We fitted a linear model describing the
decline in CD4 count over time within this patient. We recorded the slope of this relationship.
The characteristics of the cohort are summarized in Table 3.
Full genome HIV sequences and phylogeny
Full genome HIV sequences were obtained from blood samples of seroconverters taken between
6 and 24 months after seroconversion and before ART was initiated.
Table 3. Summary of the main characteristics of the cohort.
GSVL Year
sampled
Country
sampled
Transmission
mode
Sex Age at
infection
Ethnicity Subtype Sequence length
(bp)
Min.: 2.000 Min.: 1985 BE: 52 HEAM/TRANSF: 3 Female:
295
Min.: 17 Black: 36 B: 1,581 Min.: 601
1st Qu.:
4.167
1st Qu.:
2004
CH: 1,005 HET: 475 Male:
1,733
1st Qu.: 29 White: 421 A1: 113 1st Qu.: 7,669
Median:
4.675
Median:
2007
FR: 378 HET/IDU: 44 Median: 35 Other/Unknown:
1,571
02_AG:
107
Median: 9,018
Mean: 4.573 Mean: 2006 NL: 480 IDU: 90 Mean: 36 01_AE: 68 Mean: 8,168
3rd Qu.:
5.066
3rd Qu.:
2009
UK: 113 MSM: 1343 3rd Qu.: 42 C: 41 3rd Qu.: 9,068
Max.: 7.002 Max.: 2015 MSM/IDU: 1 Max.: 78 D: 25 Max.: 9,639
Other/Unknown: 72 Unknown: 445 (Other): 93
BE, Belgium; CH, Switzerland; FR, France; GSVL, gold standard viral load; HEAM/TRANSF, haemophiliac or blood transfusion; HET, heterosexual; IDU,
injecting drug user; MSM, men having sex with men; NL, the Netherlands; UK, United Kingdom.
https://doi.org/10.1371/journal.pbio.2001855.t003
Viral genetic variation explains variability in HIV-1 pathogenesis
PLOS Biology | https://doi.org/10.1371/journal.pbio.2001855 June 12, 2017 16 / 26
Sequencing and assembly. HIV genomes were amplified using a set of universal primers
[49], and sequencing was performed using Illumina MiSeq or HiSeq 2500 technology. This
generated paired-end reads, which varied in length between 100 and 300 base pairs. HIV
genome sequences were assembled for each sample using the custom pipeline ‘shiver’
described in detail elsewhere [37]. In summary, contigs were reconstructed for each sample
using the de novo assembler IVA [50]. Non-HIV contigs were removed; remaining contigs
were corrected and aligned to standard references. A new reference for mapping was then
built for each sample using the contigs, filling gaps with a set of standard whole-genome HIV
sequences [51] for positions not covered by the contigs. Reads were mapped to these custom
references using SMALT [52]. The consensus base at each position was called, resulting in a
single consensus HIV sequence for each sample. A consensus base was called at each position
where coverage exceeded 30 reads (for MiSeq technology) or 300 reads (for HiSeq technology).
An unambiguous consensus base was called when more than 60% of reads had this base.
An ambiguous base as defined by the International Union of Pure and Applied Chemistry
(IUPAC) notation was called when the most frequent base was in less than 60% of reads. The
programs Trimmomatic [53] and Fastaq [54] were used to trim adapters, PCR primers, and
low-quality bases from the reads; BLASTN [55] was used to identify contigs and reads sus-
pected of being contaminants; MAFFT [56] was used to align the contigs to references; and
SAMTOOLS [57] was used to process the mapped reads.
We processed the sequences for phylogenetic analysis as follows: we removed positions
associated with previously identified drug-resistant mutations [38,39] and CTL escape muta-
tions [40] as well as long terminal repeats. We removed positions where more than 90% of
sequences had a gap and removed sequences smaller than 500 base pairs. We inspected the
resulting alignment and removed small misaligned sequence fragments. This resulted in an
alignment of 1,373 sequences, 75% of which were more than 8,359 base pairs long (Table 3).
Subtyping. We subtyped each sequence using the COMET software [58], in particular to
identify the subset of subtype B sequences (the dominant subtype in the European HIV epi-
demic; Table 3). We verified the performance of COMET using the 199 reference sequences
of known subtype used in our alignment. COMET correctly attributed the subtype for 177 out
of the 199. Almost all subtyping mistakes consisted in imputation of the wrong circulating
recombinant form (CRFs). Most relevant to our analysis, which requires classification in B ver-
sus non-B subtypes, all 32 subtype B references were correctly classified as subtype B, except 1
that was classified as CRF 12_BF. Conversely, among all non-B references, only 2 were classi-
fied as subtype B: CRFs 48_01B and 51_01B (both of which contain subtype B sequences).
In our dataset, a number of sequences were attributed to CRFs 12_BF, 42_BF, or 17_BF.
These are most likely mistakes, as these subtypes are not commonly found in Europe. To verify
this, we additionally determined subtype by placing these sequences in a phylogenetic tree of
the references, using the software RAxML. Subtype was defined as the subtype of the reference
closest to the focal sequence in the phylogenetic tree. In most cases these sequences were
indeed attributed to subtype B with this phylogenetic method.
Phylogenetic inference. Maximum likelihood phylogenies were inferred using the soft-
ware ExaML [59]. We used the GTR model of substitution with gamma-distributed rate het-
erogeneity among sites. We inferred the phylogeny separately on 2 sets of sequences: the full
set (N = 2,028) and the subset of subtype B sequences (N = 1,581). We rooted the phylogenies
using an outgroup (20 group N, O, P, and chimpanzee SIV references for the full set and 10
subtype D references for the subset of subtype B). For the 2 sets, we inferred 10 maximum
likelihood phylogenies starting from 10 different starting points and retained the phylogeny
with maximum likelihood among them. We additionally ran 100 bootstrapped phylogenies for
each set.
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Measuring heritability using phylogenetic comparative methods
In order to measure heritability of SPVL, we fitted a series of stochastic models that describe
how viral load evolves along the branch of the tree. Under all these models, the distribution of
SPVL at the tip of the trees is a random drawing in a multivariate normal distribution whose
mean vector and variance–covariance matrix, denoted (μ, Σ), depend on the model and its
parameters and on the structure of the tree.
Brownian motion model. The BM model of evolution is classically used to explain simi-
larity among species because of shared ancestry. It is behind phylogenetic mixed models
[24,25] and Pagel’s lambda [26] and has recently been used to infer the heritability of SPVL in
HIV [29]. The model assumes the character evolves according to Brownian motion along the
phylogeny, starting from the ancestral character ga. The BM is characterized by its stochastic
variance σ2. The resulting characters at the n tips of the phylogeny are a realization of a draw in
a multivariate normal distribution with mean vector
μ ¼ gaX
(here, X is the vector of 1 of length n) and covariance matrix with elements
Si;j ¼ s
2ti;j when i 6¼ j
Si;j ¼ s
2ti;j þ 
2 when i ¼ j
where ti,j is the phylogenetic distance between the ancestor of the whole tree and the most
recent common ancestor of tips i and j, and 2 quantifies all sources of variation which are not
structured along the phylogeny, including measurement error and environmental factors. The
likelihood is then given by the probability density function of the multivariate normal distribu-
tion, that is:
  2logðLÞ ¼ n logð2pÞ þ logðjSjÞ þ ðY   gaXÞ
0
S  1ðY   gaXÞ
where |.| denotes the determinant,.' the matrix transpose, and.−1 the matrix inverse.
For each value of (σ2, 2) the parameter ga could be directly replaced by its least square esti-
mate
bga ¼ ðX
0S  1XÞ  1ðX 0S  1YÞ
Therefore, it was sufficient to optimize the likelihood with respect to (σ2, 2) only. We did
so using the Nelder–Mead method.
OU model. The OU model is similar to the BM model except that an additional force,
which can be interpreted as stabilising selection, brings the character back to an optimum
value θ [36]. The expected value of the infinitesimal change in character is E[dy] = −α(y − θ)dt,
and the stochastic variance is V[dy] = σ2dt as in the BM model. In this model, the distribution
of the character at the tips is also given by a multivariate normal distribution. The mean vector
has elements
mi ¼ ð1   e
  atiÞyþ e  ati ga
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where ti is the root to tip distance for tip i, and the covariance matrix has elements
Si;j ¼
s2
2a
ð1   e  2ati;jÞe  adi;j when i 6¼ j
Si;j ¼
s2
2a
ð1   e  2ati;jÞe  adi;j þ 2 when i ¼ j
where di,j is the patristic distance between tips i and j [36] (equal to 0 when i = j). We recover
the expressions for the BM model in the limit when α! 0. In the limit where both α and σ are
large, the covariance elements become 0 for off-diagonal elements and σ2/2α + 2 for diagonal
elements. In other words, the OU model converges to the null model, with the important dif-
ference that character variability will be interpreted as genetic instead of environmental. The
expected value of the character, starting from ga (when ti, the root-to-tip distance, is 0), con-
verges to the optimum θ with a relaxation time inversely proportional to the strength of selec-
tion α. Selection tends to erase the covariance between the characters in 2 tips, which tends to
0 as the patristic distance between the tips increases.
In the OU model, the likelihood is
  2 logðLÞ ¼ n logð2pÞ þ logðjΣjÞ þ ðY   X βÞ0Σ  1ðY   X βÞ
where X is now a matrix of dimension(n, 2), whose ith row is {1   e  ati ; e  ati}, which specifies
the relationship between the expected character value and the coefficients, in our case the opti-
mum and the ancestral character β = {θ, ga}0. As for Brownian motion, we can calculate the
maximum likelihood estimate of {θ, ga} for given values of α, σ2, 2
β ¼ ðX 0S  1XÞ  1ðX0S  1YÞ
then plug these ML estimates in the likelihood function and optimize on α, σ2, and 2 only.
In practice, when optimizing the likelihood, we set an upper limit α = 10 to avoid conver-
gence problems when both α and σ2 are large (in that limit, the 2 parameters are not
identifiable).
Adding epidemiological covariates to the regression. Epidemiological covariates affect-
ing viral load, such as sex, transmission mode, and age can be incorporated into the phyloge-
netic model by adding other columns in the matrix X. Specifically, these extra columns will be
the design matrix corresponding to the covariates of interest. Inference will then proceed as
described above, and the maximum likelihood estimates of the phylogenetic parameters bθ; bga
and the effect of covariates will be obtained by the same formula, β ¼ ðX0Σ  1XÞ  1ðX0Σ  1YÞ.
Computing the likelihood by inverting the Σmatrix would be computationally intensive for
large datasets, but faster methods exist that directly compute the products of interest for the
likelihood. We tested 3 implementations of the likelihood, which gave exactly the same result
but differ in their details and performance: (i) a slow custom code computing matrix inversion
using Cholesky decomposition, (ii) an adaptation of a linear-time algorithm developed by Ho
and Ane´ [60], and (iii) a linear-time algorithm recently developed by Mitov and Stadler [35].
We used method (ii) for its speed and easy incorporation of covariates in the linear model.
Computing confidence intervals. We quantified uncertainty on the parameters and on
heritability using parametric bootstrapping on the bootstrapped trees. This method combines
uncertainty because of finite sample size and uncertainty in the phylogenetic tree inference.
Confidence intervals represent the range of possible inferred parameters across samples if the
true parameters are the ML parameters. For each of the 100 bootstrap trees, we simulated a
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stochastic outcome of the ML model and reinferred ML parameters from these simulations.
The confidence intervals are the 2.5% and 97.5% percentiles of the resulting distribution.
To assess the significance of differences in heritability across the genome, we computed
confidence intervals reflecting only the uncertainty in phylogenetic tree inference. The herita-
bility estimates across the genome do not represent independent samples of the population but
rather the same sample with different phylogenetic relationships. For each of the 100 bootstrap
trees, we reinferred ML parameters from the data using the bootstrap tree instead of the maxi-
mum likelihood tree. The confidence intervals are the 2.5% and 97.5% percentiles of the result-
ing distribution.
Calculating heritability. Heritability of a trait is the fraction of the phenotypic variance in
a population explained by genetic factors. Heritability is defined relative to a population and
may change through time and in space. Given a subset of tips S {1, . . ., n}, the traits at these
tips are a realization of a random drawing in a multivariate normal (μS, ΣS) where the subscript
S indicates selection of elements of the subset S in the vector and matrix (μ, Σ), the overall
mean and variance for the full set of tips. In all models above, the environmental component
of the phenotype affects all traits independently, such that the covariance matrix can be rewrit-
ten Σ = Γ + In2, where Γ is the component of covariance attributable to shared ancestry and
evolution along the branches. Moreover, the vector of means can be rewritten as μ = γ + c,
where γ corresponds to the evolutionary process (a constant equal to the ancestral trait ga in
the BM model and not constant in the OU process) and c to epidemiological covariates. Thus,
the vector of phenotypes YS can be rewritten as
YS ¼ cS þ GS þ ES
where c are the predicted values corresponding to the epidemiological covariates, GS is the vec-
tor of genetic values drawn from N ðγS;ΓSÞ, and ES is the vector of environmental values
drawn from N ð0; I 2Þ. The phenotypic variance is the variance of elements in this vector. If
the size of the subset is sufficiently large that we can neglect covariances between environmen-
tal effects and other factors, the phenotypic variance (the sample variance of the trait in the
population) is
V½YS ¼ V½cS þ V½GS þ V½ES þ 2cov½cS;GS
In general, the phenotypic variance cannot be partitioned into a sum of components
corresponding to genetic variance, variance because of epidemiological covariates, and envi-
ronmental variance. This is because of the fact that the phenotypic variance is affected by
interactions between genetic values and epidemiological covariates, as quantified by
cov[cS, GS]. Assuming large size of the subset, this term will be nonzero under the OU model
when epidemiological covariates are included (i.e., the case in which the gi are not all the
same in expectation and the ci are non-null).
Heritability can be defined as the ratio of the genetic variance over the phenotypic variance,
h2S ¼
V½GS
V½YS
Heritability is a distributed quantity, and will not exactly be the same across different reali-
sations of the stochastic evolutionary process. Using simulation of the process, we can identify
the part of the simulated character contributed by genetic factors GS and compute h2. We
report results on the mean heritability computed over 1,000 stochastic simulations (Tables 1
and 2, S2 Table).
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We next compute an analytical approximation for heritability as a function of model
parameters. The full distribution of the phenotypic variance across realizations of the model
would be hard to specify, but the expected value can be computed as
E½V½YS ¼ V½cS þ E½V½GS þ E½V½ES þ 2E½cov½cS;GS
V½cS ¼
1
s
X
i2S
c2i  
1
s2
X
i2S
X
j2S
cicj
E½V½GS ¼
1
s
X
i2S
ðg2i þ Gi;iÞ  
1
s2
X
i2S
X
j2S
ðgigj þ Gi;jÞ
E½V½ES ¼ 1  
1
s
 
2
E½cov½cS;GS ¼
1
s
X
i2S
gici  
1
s2
X
i2S
X
j2S
gicj
where s is the number of elements in subset S, s = |S|. Approximating the expected value of this
ratio as the ratio of expected values, and neglecting the covariance between epidemiological
covariates and genetic values, the expected heritability is
E½h2S 
E½V½GS
E½V½YS
¼
E½V½GS
V½cS þ E½V½GS þ E½V½ES
This analytical expression for mean heritability was very accurate, as shown by systematic
comparison with the mean heritability obtained across 1,000 simulations. The covariance
between epidemiological covariates and genetic values, E[cov[cS, GS]], was always very small in
our dataset.
Supporting information
S1 Fig. Maximum likelihood subtype B phylogeny. The maximum likelihood phylogeny of
viral sequences of subtype B used for the estimation of heritability (N = 1581), with edges
coloured by viral load value (in log10 copies/mL). Black points show nodes with bootstrap
values greater than 90%. The data used in the figure is provided as supplementary informa-
tion.
(EPS)
S2 Fig. Estimated heritability as a function of sample size. Estimated heritability under the
BM (top panel) and OU (bottom panel) models, as a function of sample size. We randomly
sampled 40 subsets of the full dataset (subtype B only, N = 1581) and inferred maximum likeli-
hood parameters and heritability in each subset. Bullets show the maximum likelihood herita-
bility and gray lines show the bootstrap confidence intervals. The dashed line represents the
maximum likelihood estimate for the full dataset (N = 1581, point on the right). The data used
in the figure is provided as supplementary information.
(EPS)
S3 Fig. Increase in phenotypic variance in the data and predicted increase in genetic vari-
ance in the phylogenetic models. Bullets show the variance in GSVL (black) and SPVL (gray)
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among subtype B samples as a function of the time of the sample, calculated over 2-years inter-
vals. The corresponding lines show the linear regression, with a significant increase for GSVL
but not for SPVL when adjusting for covariates (S1 Table). Dotted lines show the predicted
increase in genetic variance under the maximum likelihood OU model. Dashed lines show the
predicted increase in genetic variance under the maximum likelihood BM model. These pre-
dictions were computed by simulating the maximum likelihood model, and calculating the
mean genetic variance over 1000 realisations of the process and for each set of tips (corre-
sponding to patients sampled in 1985–1986, 1987–1988, etc). The data used in the figure is
provided in S1 Data.
(EPS)
S4 Fig. Linkage disequilibrium in the population as a function of the distance separating
pairs of loci. We considered all subtype B sequences (N = 1581), and calculated the linkage
disequilibrium for 100,000 pairs of positions where the two most common nucleotides
have frequency greater than 0.01. Linkage disequilibrium was calculated as D = (XAB-pA pB)/p
[pA (1-pA) pB (1-pB)] where A denotes the most common allele (nucleotide) at the first posi-
tion, B denotes the most common allele at the second position, XAB is the frequency of the
genotype AB and pA and pB the frequencies of alleles A and B (ignoring other nucleotides pres-
ent at smaller frequencies at the locus). Positive linkage indicates association between the two
most common alleles. We show average linkage disequilibrium as function of the distance
between positions. Weak positive linkage even at long distances may be due to shared ancestry.
The data used in the figure is provided in S1 Data.
(EPS)
S5 Fig. Schematic of a donor-recipient pair. On the left, the genealogy of a donor transmit-
ting to a recipient. Arrows denote the time of sampling and measurement of each partner. We
assume the donor is measured and sampled before the branching in the genealogy (which may
be anterior to the transmission event because of within-host diversity). On the right, the result-
ing phylogeny. We assume the donor trait is equal to the trait of the MRCA of the donor and
the recipient.
(EPS)
S1 Table. Analysis of temporal trends in GSVL and SPVL.
(DOCX)
S2 Table. Analysis of heritability stratified by country, gender, mode of transmission.
(DOCX)
S3 Table. Analysis of heritability for another viral load measure, for a linear model with
country included as a covariate, and for other inclusion criteria for viral sequences.
(DOCX)
S4 Table. Analysis of variance for three viral load measures, for the subset of patients
infected by subtype B virus.
(DOCX)
S5 Table. Analysis of variance for GSVL and SPVL viral load measures, for patients
infected by all subtypes (N = 2028).
(DOCX)
S1 Text. The relationship between SPVL and GSVL.
(DOCX)
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S2 Text. The relationship between phylogenetic heritability and donor-recipient regres-
sion.
(DOCX)
S3 Text. Cohort members.
(DOCX)
S1 Data. Data for Figs 1B, 1C, 2, S2, S3 and S4.
(ZIP)
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